PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)Evangelia Pantazaka, Galatea Kallergi|Biomedicines|2022Cited by 11